Gilead Sciences Says Study of GS-6207 Showed HIV Capsid Inhibition Can Lead Viral Load Declines
July 22 2019 - 11:51AM
Dow Jones News
By Stephen Nakrosis
Gilead Sciences, Inc. (GILD) said Monday data from a Phase 1b
study of its GS-6207 demonstrated "the first proof of concept that
HIV capsid inhibition can lead to significant declines in viral
load in vivo."
Gilead said GS-6207 is "an investigational long-acting
antiretroviral agent," which was recently given a breakthrough
therapy designation by the U.S. Food and Drug Administration.
GS-6207 is a "potential therapy for heavily treatment-experienced
people living with multi-drug resistant HIV," the company said.
Gilead said GS-6207 acts to interrupt "the activity of HIV
capsid, a protein that surrounds and protects the virus' genetic
material and essential enzymes." The company said it can
potentially keep the virus from becoming infectious and accessing
uninfected cells.
Gilead said the treatment's safety and efficacy have yet to be
established.
Data from the study was presented at the International AIDS
Society Conference on HIV Science in Mexico City.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 22, 2019 11:36 ET (15:36 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024